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Edited by Veli-Pekka LehtoAbstract Prostaglandins are potent mediators of the inﬂam-
matory response and are also involved in cancer development. In
this study, we show that human melanocytes and FM55
melanoma cells express cyclooxygenase-1 and -2 (COX-1 and
-2) and thus have the capability to produce prostaglandins. The
FM55 cells produced predominantly PGE2 and PGF2a, whereas
the HaCaT keratinocyte cell line produced mainly PGE2. The
anti-inﬂammatory peptide, a-melanocyte stimulating hormone
(a-MSH), reduced prostaglandin production in FM55 and
HaCaT cells and reversed the eﬀect of the pro-inﬂammatory
cytokine TNF-a in the former. These results indicate that
melanocytes produce prostaglandins and that a-MSH, by
inhibiting this response, may play an important role in regulating
inﬂammatory responses in the skin.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Prostaglandins are lipid-derived mediators that have a wide
spectrum of biological activities that is determined by their
tissue of origin [1,2]. In the skin they mediate inﬂammatory
reactions, although the sequence of events involved in these
responses is poorly understood. The cellular origin of these
mediators in the skin is also not clear, although it is generally
suspected that a major source is the keratinocyte. The possi-
bility should be considered that melanocytes are a source of
prostaglandins. These cells, which are best known for their
pigment production, are capable of secreting inﬂammatory
mediators such as nitric oxide (NO) and numerous cytokines
[3]. Recently, human malignant melanoma cells were shown to
over-express cyclooxygenase-2 (COX-2) [4–6], the inducible* Corresponding author. Fax: +44-1274-235600.
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doi:10.1016/j.febslet.2004.06.041isoform of COX which is the rate-limiting enzyme in the
production of prostanoids. Increased expression of COX-2 has
been linked to the development and progression of malignant
epithelial cancers [7], raising the possibility that prostaglandins
produced by melanocytic cells have a functional role in skin
carcinogenesis.
Melanocyte function is regulated by a-melanocyte stimu-
lating hormone (a-MSH). It is also recognized that a-MSH
and related proopiomelanocortin-derived peptides are pro-
duced in the skin where they act as autocrine and paracrine
regulators of skin pigmentary and immune systems [8]. a-MSH
stimulates melanin synthesis in addition to other actions in
melanocytic cells [3]. Thus, in human melanocytes it inhibits
UV-induced apoptosis [9]. In addition, it has been shown to
protect against proinﬂammatory cytokine attack and reduce
invasion in melanoma cells [10]. a-MSH also modulates NO
production by melanocytes and melanoma cells by regulating
the expression of iNOS [11]. Assuming that melanocytes pro-
duce prostaglandins, it is then possible that this process will be
regulated by a-MSH. Such an action would be in keeping with
its role as an anti-inﬂammatory, anti-pyretic and immuno-
regulatory peptide [12]. Interestingly, these immunoregulatory
actions of a-MSH are mediated by the same melanocortin
receptor subtype, namely the MC1R, that is expressed on
melanocytes.
The purpose of the present study was to examine the pro-
duction of prostaglandins by melanocytes and to see whether
this function is aﬀected by a-MSH.2. Materials and methods
2.1. Materials
Phosphate-buﬀered saline, dimethylsulfoxide, calcium ionophore
A23187, dithiothreitol, phospholipid standards and anhydrous sodium
sulfate were obtained from Sigma, Poole, UK. Primary prostaglandin
HPLC mixture and PGB2 were from Cayman Chemicals, Ann Arbor,
USA. 14C-Arachidonic acid was purchased from Amersham Bio-
sciences, Chalfont St Giles, UK. HPLC grade methanol, glacial acetic
acid, acetonitrile, ethyl acetate, and absolute ethanol were purchased
from VWR, Lutterworth, UK. Detergent-compatible protein assay kit
was from Bio-Rad, Hemel Hampstead, UK.
2.2. Cell culture
Human epidermal melanocytes and keratinocytes were isolated from
skin samples from adults undergoing plastic surgery at the Bradford
Royal Inﬁrmary (according to the protocol approved by the local
ethics committee). The cells were cultured in supplemented MCDB 153ation of European Biochemical Societies.
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established from metastatic melanoma nodules was a gift from Dr.
A.F. Kirkin (Danish Cancer Society, Copenhagen, Denmark). FM55
human melanoma cells were maintained in RPMI-1640 medium
(Gibco-BRL, UK) and HaCaT cells in DMEM (Gibco-BRL) con-
taining 10% foetal bovine serum (ICN Flow, Basingstoke, UK) and
penicillin (50 IU/ml)/streptomycin (50 lg/ml) (Gibco-BRL). All cul-
tures were kept in a humidiﬁed atmosphere at 37 C, 5% CO2.
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from approximately 5 105 cells using
Tri-reagent according to the manufacturer’s instructions (Invitrogen,
Paisley, UK). About 1–5 lg of total RNA was reverse transcribed
using oligo(dT) as primers and Super Script II reverse transcriptase
(Gibco-BRL). The products were ampliﬁed using gene speciﬁc primers:
(i) COX-1 sense 50-tgcccagctcctggcccgccgct-30 and COX-1 antisense
50-gtgcatcaacacaggcgcctctt-30; (ii) COX-2 sense 50-ttcaaatgagattgt-
ggaaaaattgct-30 and COX-2 antisense 50-agatcatctctgcctgagtatctt-30.
The primer sets yield PCR products of 303 and 304 bp for COX-1 and
COX-2, respectively. For both COX-1 and COX-2 gene ampliﬁcation,
samples contained 10 pmol of each primer, 200 lM dNTP, 2 mM
MgCl2, 1 PCR buﬀer, 1U Taq polymerase and 1 ll cDNA to a ﬁnal
volume of 50 ll. Reaction mixtures were incubated in a thermal cycler
(PCR Sprint temperature cycling system, Hybaid, UK) for 38 cycles
(10 cycles of denaturation for 30 s at 94 C, annealing for 45 s at 65 C
and extension for 1 min at 72 C and 28 cycles of denaturation for 30 s
at 94 C, annealing for 45 s at 58 C and extension for 1 min at 72 C).
Negative control experiments were performed using the reaction
mixture and primers without cDNA. Finally, the PCR products were
separated on a 1.5% agarose gel, stained with ethidium bromide and
photographed under UV.
2.4. Resting production of 14C-prostaglandins
Cells were cultured to approximately 80% conﬂuence. They were
then transferred to fresh serum free medium and quiesed for 3 h. At the
end of this period, the medium was changed to serum free medium
containing 14C-arachidonic acid (14C-AA) (1 lCi) and the cells were
incubated for 3 h. The medium containing 14C-prostaglandins
produced during the 14C-AA incubation was removed and stored at
)20 C awaiting analysis.
2.5. Stimulated production of 14C-eicosanoids
Cells were cultured to approximately 80% conﬂuence and treated
with 14C-AA (1 lCi) as previously described. The medium was then
removed and the cells washed twice with serum free medium to ensure
complete removal of excess 14C-AA. Serum free medium (5 ml) con-
taining calcium chloride (2 mM) and calcium ionophore A23187 (3 M)
was then added to stimulate prostaglandin production and the cells
were incubated for a further 30 min. The medium, containing 14C-
prostaglandins, was removed and stored at )20 C awaiting analysis.
2.6. Inhibition of 14C-prostaglandin production by indomethacin
Production of 14C-prostaglandins was inhibited by indomethacin (3
mM) [14]. Inhibition of basal 14C-eicosanoids was achieved by adding
the indomethacin solution and 14C-AA to the cells simultaneously.
Inhibition of stimulated 14C-prostaglandins was achieved by adding
the indomethacin solution to the labelled cells 10 min prior to adding
calcium ionophore. In both cases, cells and media were treated in the
same way as already described for basal and stimulated production of
14C-prostaglandins.
2.7. Eﬀect of TNF-a and a-MSH on 14C-prostaglandin production
Cells were labelled with 14C-AA (1 lCi) for 3 h as previously de-
scribed. TNF-a (500 IU) and/or a-MSH (108 M) were then added and
the cells were incubated for a further 24 h. The 14C-prostaglandin
containing medium was collected and stored at )20 C awaiting
analysis.
2.8. Extraction of 14C-prostaglandins
Internal standard (PGB2 500 ng) was added to each sample of me-
dium containing 14C-prostaglandins [14]. The resulting solution was
acidiﬁed with 1 M citric acid to pH 3.0 and the 14C-prostaglandins
were extracted by adding 2 vol of ethyl acetate. The ethyl acetate ex-
tract was dried with anhydrous Na2SO4, the organic solvent evapo-
rated under nitrogen and stored at )20 C awaiting analysis.Appropriate control experiments using commercially available pros-
taglandin standards were performed to ensure the reliability of the
extraction procedure.
2.9. HPLC analysis of 14C-prostaglandins
14C-prostaglandins were separated by HPLC performed on a C18
Spherisorb ODS2 column (4.5 250 mm, 5 mm, Waters) with a C18
ODS2 (5 lm) guard-column (Alltech). The mobile phase consisted of
acetonitrile:water:glacial acetic acid (45:55:0.02 v/v). The 14C-prosta-
glandin extracts were reconstituted in mobile phase. The ﬂow rate was
0.5 ml/min. Fractions were collected at 30s intervals and 14C-metab-
olites were detected by liquid scintillation counting. 14C-prostaglandins
were identiﬁed by co-elution with unlabelled standards as detected at
192 nm (Waters 486 UV detector). The internal standard (PGB2) was
detected at 280 nm [14].
2.10. Measurement of cell viability
At the end of all experiments, cells were trypsinized and counted
using a heamocytometer. Cell viability was assessed by the trypan blue
exclusion assay and was found to be greater than 95% for all experi-
ments.
2.11. Protein assay
Cell pellets from all experiments were dissolved in 1% SDS, boiled
for 10 min and protein measurements were carried out using the DC
protein assay kit (Bio-Rad, UK) according to the manufacturer’s
instructions.
2.12. Calculations and statistical analysis
All data are expressed as mean values S.D. of at least three inde-
pendent determinations unless otherwise stated. Statistical analyses
were performed using Student’s independent samples two-tailed t-test.
All tests were performed with the SPSS 11.0 Software.3. Results
3.1. Melanocytes express COX-1 and COX-2
Using RT-PCR, the presence of mRNA for both COX-1
and COX-2 was detected in the primary cultures of human
melanocytes and keratinocytes, as well as in human FM55
melanoma and HaCaT keratinocyte cell lines. The results are
shown in Fig. 1. Keratinocytes and HaCaT cells are known to
express COX-2 [15,16] and were included in the present study
for comparison purposes.
3.2. Production and proﬁle of prostaglandins
Because of the limited availability of clinical material for
primary cultures, detailed studies on the proﬁle of prosta-
glandins were carried out in FM55 melanoma and HaCaT
cells.
The proﬁle of prostaglandins produced by FM55 melanoma
cells and HaCaT keratinocytes was investigated using 14C-AA-
labelled cells. Under resting conditions, 14C-AA was converted
into three 14C-labelled prostaglandins, which were identiﬁed as
PGF2a, PGE2 and PGD2. This production was seen both in
FM55 melanoma and HaCaT keratinocytes (Fig. 2). In the
FM55 melanoma approximately similar amounts of PGF2a,
PGE2 and PGD2 were produced (Fig. 2A), whereas in the
HaCaT cells PGE2 was found to be the most abundant
product (Fig. 2B). The level of incorporation of 14C-AA ten-
ded to be slightly higher in the HaCaT cells although there was
some variation between experiments (data not shown).
Stimulation of 14C-prostaglandin with calcium ionophore
A23187 was examined in FM55 and HaCaT cells. Calcium
ionophore stimulates phospholipase A2 activity with con-
comitant release of arachidonic acid from the cells leading to
acute stimulation of eicosanoid production. This treatment
Fig. 1. Expression of COX-1 and COX-2 mRNA in melanocytic cells
and keratinocytes. Lane 1: Human melanocytes; lane 2: FM55 mela-
noma cells; lane 3: human keratinocytes; lane 4: HaCaT keratinocytes;
lane 5: negative control; lane 6: molecular weight markers.
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Fig. 2. 14C-Prostaglandins produced by FM55 melanoma (A) and
HaCaT keratinocytes (B) under resting and stimulated conditions.
Indomethacin (3 mM) inhibited resting (resting+ IND) and stimulated
(stimulated+ IND) 14C-prostaglandin production. The results are ex-
pressed as meansS.D. of at least three independent determinations.
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Fig. 3. The eﬀect of a-MSH alone and in the presence of TNF-a on the
production of 14C-prostaglandins by FM55 melanocyte cells. The re-
sults are expressed as means S.D. of at least three independent de-
terminations. *P < 0:05 and **P < 0:01 comparing all treatments to
control; #P < 0:005 comparing TNF-a treatment to a-MSH treatment;
$P < 0:05 comparing a-MSH+TNF-a treatment to TNF-a treatment.
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Fig. 4. The eﬀect of a-MSH alone and in the presence of TNF-a on the
production of 14C-prostaglandins by HaCaT keratinocyte cells. The
results are expressed as meansS.D. of at least three independent
determinations. *P < 0:05 comparing all treatments to control.
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changes in their proﬁle (Fig. 2A and B). In the FM55 cells the
production of PGF2a was more than doubled, with smaller
increases in PGE2 and PGD2 (Fig. 2A). In the HaCaT cells,
there was a doubling in the production of PGE2 and PGF2a
(Fig. 2B). Furthermore, incubation with indomethacin (COX-
1 and COX-2 inhibitor) inhibited resting and stimulated 14C-
prostaglandin production in both FM55 and HaCaT cells,thus conﬁrming that the observed 14C-metabolites were COX
products (Fig. 2).
3.3. Eﬀect of a-MSH on prostaglandin production
It has been reported that a-MSH can oppose the action of
the pro-inﬂammatory cytokine TNF-a in melanocytes and
melanoma cells [17]. Therefore, TNF-a was used as stimuli for
prostaglandin production with a view to explore whether in-
hibition of prostaglandins contributes to the anti-inﬂamma-
tory action of a-MSH. a-MSH inhibited 14C-PGF2a
production in FM55 melanoma cells and reversed the TNF-a-
induced PGE2 production in these cells by approximately 80%
(Fig. 3). It also reduced 14C-PGF2a production in HaCaT cells
(Fig. 4) but in contrast to its eﬀects in the FM55 cells failed to
alter prostaglandin production in the presence of TNF-a.
TNF-a alone had no eﬀect on the production of prostaglan-
dins in the HaCaT cells (Fig. 4).
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It is considered that a major source of prostaglandins in the
skin is the keratinocyte. Our ﬁndings show that melanocytes
express COX-1 and -2, suggesting that these cells are a po-
tential source of prostaglandins. One of the recognized func-
tions of the melanocyte is the production of melanin which is
transferred into keratinocytes where it protects against UV
induced damage [3]. Prostaglandins may be involved in regu-
lating this function, since they have been shown to stimulate
melanogenesis in iridial melanocytes [18]. In addition, it has
been suggested that PGE2 has a role in post-inﬂammatory
pigmentation [19]. Thus, prostaglandins may act as local reg-
ulators of skin pigmentation. They could aﬀect melanocyte
function in other ways. For instance, since COX-2 is expressed
in melanoma cells and is implicated in tumour development
[4–6] prostaglandins could aﬀect the progression of melano-
cytes to malignant phenotypes. Whatever the signiﬁcance of
prostaglandins for melanocyte function, their production by
melanocytes could contribute to inﬂammatory responses in the
skin.
Our ﬁndings show that FM55 melanocytes express both
isoforms of COX (COX-1 and -2), and produce an array of
prostaglandins under basal and stimulated conditions. When
these cells were stimulated with calcium ionophore, the pro-
duction of PGF2a was increased with no change in the
amounts of PGE2 and PGD2. This diﬀered from the situation
in HaCaT cells where PGE2 was the main metabolite. Fur-
thermore, whereas the proinﬂammatory cytokine TNF-a in-
creased PGE2 production in the FM55 cells, it was found to
have no eﬀect on the prostaglandin production by HaCaT
keratinocytes. This lack of eﬀect in HaCaT cells was surprising
in view of previous reports that TNF-a will stimulate COX-2
expression and prostaglandin production in transformed hu-
man keratinocytes [20], and induce NFjB activation in HaCaT
keratinocytes [21]. Nevertheless, our ﬁndings indicate that the
proﬁle of prostaglandin production in melanocytic cells may
diﬀer from that in keratinocytes and especially in response to
inﬂammatory stimuli. This could have important implications
in inﬂammatory situations in the skin and warrants further
investigation.
The observed inhibition of prostaglandin production in
FM55 melanoma and HaCaT keratinocytes by a-MSH sup-
ports the view that this peptide has anti-inﬂammatory prop-
erties. Its ability to reverse the action of TNF-a in FM55 cells
is consistent with previous reports that this peptide is able to
antagonize the actions of pro-inﬂammatory cytokines [22,23].
Through its ability to stimulate melanogenesis in melanocytes,
a-MSH has an important role as a mediator in UV induced
skin pigmentation [3]. This induced tanning can be preceded by
erythema and, since PGE2 is involved [24], a-MSH might be
expected to reduce this response. These actions of a-MSH may
explain the inverse relationship between tanning ability and
UV induced erythema seen in some individuals. It may also
explain why individuals with loss of function mutations at the
MC1R show an increased risk of erythema following UV. If
prostaglandins are involved in the more long term eﬀects of
UV, such as photoaging and carcinogenesis [24], then a-MSH
could act to suppress these eﬀects. In the long term, UV irra-diation can lead to the development of skin cancer [25] and if,
as suspected, changes in prostaglandin production are involved
(see Introduction) then a-MSH could be protective. Since
COX-2 is implicated in tumour development, including ma-
lignant melanoma [4–7], then further studies to explore the
eﬀect of a-MSH on the expression of this COX would be
worthwhile.
Acknowledgements: This work was supported by Stiefel Laboratories
(UK) Ltd. and The Wellcome Trust.References
[1] Nicolaou, A. (2004) in: Nicolaou, A., Kokotos, G., (Eds.),
Bioactive Lipids, Oily Press. (in press).
[2] Smith, K.J. and Skelton, H. (2002) J. Cutan. Med. Surg. 6, 241–
256.
[3] Tsatmali, M., Ancans, J. and Thody, A.J. (2002) J. Histochem.
Cytochem. 50, 125–133.
[4] Goulet, A.C. et al. (2003) Cancer Biol. Ther. 2, 713–718.
[5] Denkert, C., Kobel, M., Berger, S., Siegert, A., Leclere, A.,
Trefzer, U. and Hauptmann, S. (2001) Cancer Res. 61, 303–308.
[6] Higashi, Y., Kanekura, T. and Kanzaki, T. (2000) Int. J. Cancer
86, 667–671.
[7] Bishop-Bailey, D., Calatayud, S., Warner, T.D., Hla, T. and
Mitchell, J.A. (2002) J. Environ. Pathol. Toxicol. Oncol. 21, 93–
101.
[8] Slominski, A., Wortsman, J., Luger, T., Paus, R. and Solomon, S.
(2000) Physiol. Rev. 80, 979–1020.
[9] Kadekaro, A.L., Kanto, H., Kavanagh, R. and Abdel-Malek,
Z.A. (2003) Ann. NY Acad. Sci. 994, 359–365.
[10] Eves, P. et al. (2003) Br. J. Cancer 89, 2004–2015.
[11] Tsatmali, M., Graham, A., Szatkowski, D., Ancans, J., Manning,
P., McNeil, C.J., Graham, A.M. and Thody, A.J. (2000) J. Invest.
Dermatol. 114, 520–526.
[12] Luger, T.A., Scholzen, T.E., Brzoska, T. and Bohm, M. (2003)
Ann. NY Acad. Sci. 994, 133–140.
[13] Hunt, G. and Thody, A.J. (1994) Cell and Tissue Culture:
Laboratory Procedures. Wiley, Chistester. Chapter 11.
[14] Urquhart, P., Parkin, S.M., Rogers, J.S., Bosley, J.A. and
Nicolaou, A. (2002) Biochim. Biophys. Acta 28, 2–3.
[15] Buckman, S.Y., Gresham, A., Hale, P., Hruza, G., Anast, J.,
Masferrer, J. and Pentland, A.P. (1998) Carcinogenesis 19, 723–
729.
[16] Bachelor, M.A., Silvers, A.L. and Bowden, G.T. (2002) Oncogene
21, 7092–7099.
[17] Hedley, S.J., Gawkrodger, D.J., Weetman, A.P., Morandini, R.,
Boeynaems, J.M., Ghanem, G. and Neil, S.M. (1998) Br. J.
Dermatol. 138, 536–543.
[18] Stjernschantz, J.W., Albert, D.M., Hu, D.N., Drago, F. and
Wistrand, P.J. (2002) Surv. Ophthalmol. 47, S162–S175.
[19] Tomita, Y., Maeda, K. and Tagami, H. (1992) Pigm. Cell. Res. 5,
357–361.
[20] Grewe, M., Trefzer, U., Ballhorn, A., Gyufko, K., Henninger, H.
and Krutmann, J. (1993) J. Invest. Dermatol. 101, 528–531.
[21] Shiratori, K., Ohgami, K., Ilieva, I.B., Koyama, Y., Yoshida, K.
and Ohno, S. (2004) Invest. Ophthalmol. Vis. Sci. 45, 159–164.
[22] Haycock, J.W., Rowe, S.J., Cartledge, S., Wyatt, A., Ghanem, G.,
Morandini, R., Rennie, I.G. and MacNeil, S. (2000) J. Biol.
Chem. 275, 15629–15636.
[23] Moustafa, M., Szabo, M., Ghanem, G.E., Morandini, R., Kemp,
E.H., MacNeil, S. and Haycock, J.W. (2002) J. Invest. Dermatol.
119, 1244–1253.
[24] Rhodes, L.E., Belgi, G., Parslew, R., McLoughlin, L., Clough,
G.F. and Friedmann, P.S. (2001) J. Invest. Dermatol. 117, 880–
885.
[25] Matsumura, Y. and Ananthaswamy, H.N. (2002) Expert Rev.
Mol. Med. 2, 1–22.
